These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 37172528)
1. The clinicopathological significance of TOP2A expression in malignant peritoneal mesothelioma. Du X; Li X; Zhang B; Hao Z; Gao Y; Jiang X; Yang Z; Chen Y Ann Diagn Pathol; 2023 Aug; 65():152155. PubMed ID: 37172528 [TBL] [Abstract][Full Text] [Related]
2. Comparison of SKIP expression in malignant pleural mesotheliomas with Ki-67 proliferation index and prognostic parameters. Türkcü G; AlabalIk U; Keles AN; Ibiloglu I; Küçüköner M; Sen HS; Büyükbayram H Pol J Pathol; 2016 Jun; 67(2):108-13. PubMed ID: 27543864 [TBL] [Abstract][Full Text] [Related]
3. Loss of NPM2 expression is a potential immunohistochemical marker for malignant peritoneal mesothelioma: a single-center study of 92 cases. Wu HL; Yang ZR; Su YD; Ma R; Du XM; Gao Y; Li Y World J Surg Oncol; 2022 Oct; 20(1):350. PubMed ID: 36280841 [TBL] [Abstract][Full Text] [Related]
5. Methylthioadenosine Phosphorylase and Breast Cancer 1 Protein-Associated Protein 1 as Biomarkers for the Peritoneal Mesothelioma. Chen Y; Du X; Gao Y; Wu H; Zhao H; Su Y Cancer Control; 2023; 30():10732748231220805. PubMed ID: 38092371 [TBL] [Abstract][Full Text] [Related]
6. Prognostic role of CD74, CD10 and Ki-67 immunohistochemical expression in patients with diffuse malignant peritoneal mesothelioma: a retrospective study. Liang Y; Li C; Liu Y; Tian L; Yang D BMC Cancer; 2023 May; 23(1):406. PubMed ID: 37147569 [TBL] [Abstract][Full Text] [Related]
7. Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization array. Chirac P; Maillet D; Leprêtre F; Isaac S; Glehen O; Figeac M; Villeneuve L; Péron J; Gibson F; Galateau-Sallé F; Gilly FN; Brevet M Hum Pathol; 2016 Sep; 55():72-82. PubMed ID: 27184482 [TBL] [Abstract][Full Text] [Related]
8. The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Kusamura S; Torres Mesa PA; Cabras A; Baratti D; Deraco M Ann Surg Oncol; 2016 May; 23(5):1468-73. PubMed ID: 26572754 [TBL] [Abstract][Full Text] [Related]
10. Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma. Kaya H; Sezgı C; Tanrıkulu AC; Taylan M; Abakay O; Sen HS; Abakay A; Kucukoner M; Kapan M Neoplasma; 2014; 61(4):433-8. PubMed ID: 24645844 [TBL] [Abstract][Full Text] [Related]
11. [Expression and prognostic significance of KAP1 gene in malignant pleural mesothelioma]. Mei W; Wang XM; Liu RA; Xiong W; Zhang YP Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2024 Apr; 42(4):258-267. PubMed ID: 38677988 [No Abstract] [Full Text] [Related]
12. Immunohistochemical Evaluation of Minichromosome Maintenance Protein 7 (MCM7), Topoisomerase IIα, and Ki-67 in Diffuse Malignant Peritoneal Mesothelioma Patients Using Tissue Microarray. Deraco M; Cabras A; Baratti D; Kusamura S Ann Surg Oncol; 2015 Dec; 22(13):4344-51. PubMed ID: 25777091 [TBL] [Abstract][Full Text] [Related]
13. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects. Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567 [TBL] [Abstract][Full Text] [Related]
14. Clinical and pathologic predictors of clinical outcome of malignant pleural mesothelioma. Berardi R; Fiordoliva I; De Lisa M; Ballatore Z; Caramanti M; Morgese F; Savini A; Rinaldi S; Torniai M; Tiberi M; Ferrini C; Onofri A; Cascinu S Tumori; 2016; 102(2):190-5. PubMed ID: 26893272 [TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical Expression of Aquaporin-1 in Fluoro-Edenite-Induced Malignant Mesothelioma: A Preliminary Report. Angelico G; Caltabiano R; Loreto C; Ieni A; Tuccari G; Ledda C; Rapisarda V Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495596 [TBL] [Abstract][Full Text] [Related]
16. Clinical-pathological characteristics and prognostic factors for malignant peritoneal mesothelioma in the elderly. Pan D; Wang M; Liu W; Li Y; Sang L; Chang B BMC Gastroenterol; 2022 Jun; 22(1):292. PubMed ID: 35681152 [TBL] [Abstract][Full Text] [Related]
17. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy]. Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167 [No Abstract] [Full Text] [Related]
18. IMP3 as a prognostic biomarker in patients with malignant peritoneal mesothelioma. Hui S; Guo-Qi Z; Xiao-Zhong G; Chun-Rong L; Yu-Fei L; Dong-Liang Y Hum Pathol; 2018 Nov; 81():138-147. PubMed ID: 30031101 [TBL] [Abstract][Full Text] [Related]
19. Malignant pleural mesothelioma incidence and survival in the Republic of Ireland 1994-2009. Jennings CJ; Walsh PM; Deady S; Harvey BJ; Thomas W Cancer Epidemiol; 2014 Feb; 38(1):35-41. PubMed ID: 24394956 [TBL] [Abstract][Full Text] [Related]
20. [Expression and clinical significance of SETD2 in maligant pleural mesothelioma]. Yu M; Yu M; Zhu LJ; Yuan XY; Zhang X Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2021 Feb; 39(2):91-98. PubMed ID: 33691361 [No Abstract] [Full Text] [Related] [Next] [New Search]